Zyvox Not Major Treatment Expense, CMS Says; Add-On Payments Denied
Executive Summary
Pharmacia's Zyvox is not a significant factor in the total cost of treating patients receiving the product, the Centers for Medicare & Medicaid Services determined in denying add-on payments for the antibiotic
You may also be interested in...
Zyvox Medicare “Add-On” Payments Denied; CMS Wary Of Precedent
The denial of Medicare "add-on" payments for Pharmacia's Zyvox reflects CMS' desire to avoid a precedent that could make numerous older therapies eligible for enhanced reimbursement, the agency said in an Aug. 1 final rule implementing changes to the hospital in-patient payment system
Zyvox Medicare “Add-On” Payments Denied; CMS Wary Of Precedent
The denial of Medicare "add-on" payments for Pharmacia's Zyvox reflects CMS' desire to avoid a precedent that could make numerous older therapies eligible for enhanced reimbursement, the agency said in an Aug. 1 final rule implementing changes to the hospital in-patient payment system
Lilly Xigris Add-On Medicare Payment Decision Awaits Further CMS Analysis
The Centers for Medicare & Medicaid Services may consider providing add-on Medicare payments for Lilly's sepsis agent Xigris for a narrower patient population than FDA's approved indication